Medicines for Malaria Venture welcomes the report on antimicrobial resistance. Antimalarial resistance is a major challenge which is not included in the report. Widespread resistance to the drugs used in current therapies could result in a public health catastrophe, particularly in Africa, and it is critical to act now, support the WHO strategy, preserve the efficacy of existing medicines and develop next-generation tools. This point was made in a side event organized earlier this week by eight African Member States, Africa CDC, MMV and the RBM Partnership to End Malaria. MMV recommends including the threat of antimalarial resistance in the forthcoming update of the WHO global action plan on antimicrobial resistance.